Abstract
Cognitive impairment is a well recognized feature of patients with Parkinson’s disease as well as Alzheimer’s distice. Although the pattern of cognitive dysfunction is not identical, the two diseases share many neuropathological1 and neurochemical2 features. This study was conducted to compare the brain perfusion image using three-dimensional surface (3D) display in Parkinson’s disease with that in Alzheimer’s disease. 3D surface display may be superior to tomographic images for diagnosing the extent of cerebral cortical hypoperfusion,3 since the physician must integrate information from a large number of single photon emission computed tomography (SPECT) images to evaluate low perfusion lesions stereoscopically.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.M. Candy, R.H. Perry, E.K. Perry, D. Irving, G. Blessed, A.F. Fairbrain, and B.E. Tomlinson Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s disease, J. Neurol. Sci. 59: 277–289 (1983).
M. Ruberg, A. Ploska, F. Javoy-Agid, and Y. Agid, Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia, Brain Res. 232: 129–139 (1982).
N. Honda, K. Machida, T. Mamiya, T. Takabashi, T. Takishima, T. Kamano, S. Tamaki, M. Muramatsu, and R. Ban, Value of three-dimensional surface display of brain perfusion imaging. Comparison with tomographic imaging, Clin. Nucl. Med. 17: 106–109 (1992).
J. Ishimura, M. Fukuchi, Clinical application of three dimensional surface display in brain imaging with Tc-99m HMPAO, Clin. Nucl. Med. 16: 343–351 (1991).
K.A. Johnson, S.T. Mueller, T.M. Walshe, R.I. English, and B.L. Holman, Cerebral perfusion imaging in Alzheimer’s disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch. Neurol. 44: 165–168 (1987).
I. Goto, T. Taniwaki, S. Hosokawa, M. Otsuka, Y. Ichiva, and A. Ichimiva, Positron emission tomo graphic (PET) studies in dementia, J. Neurol. Sci. 114: 1–6 (1993).
G.T. Lenzi, T. Jones, J.L. Reid, and S. Moss, Regional impairment of cerebral oxidative metabolism in Parkinson’s disease, J. Neurol. Neurosurg. Psychiatry 42: 59–62 (1979).
P.T. Fox, M.E. Raichle, M.A. Mintun, and C. Dence, Nonoxidative glucose consumption during focal physiologic neural activity, Science 241: 462–464 (1988).
W.R.G. Gibb, Dementia and Parkinson’s disease, Br. J. Psychiatry 154: 596–614 (1989).
R.S. Hellman, R.S. Tikofsky, B.D. Collier, R.G. Hoffman, D.W. Palmer, S.L. Glatt, P.G. Antuono, A.T. Isitman, and R.A. Papke, Alzheimer disease: Quantitative analysis of I-123-Iodoamphetamine SPECT brain imaging, Radiology 172: 183–188 (1989).
B.L. Holman, K.A. Johnson, B. Gerada, P.A. Carvalho, and A. Satlin, The scintigraphic appearance of Alzheimer’s disease• a prospective study using technetium-99m-HMPAO SPECT, J. Nucl. Med. 33: 181–185 (1992).
F. Boller, T. Mizutani, U. Roessmann, and P. Gambetti, Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations, Ann. Neurol. 7: 329–335 (1980).
H.O. Habert, U. Spampinato, J.L. Mas, M.L. Piketty, M.C. Bourdel, J. de Recondo, P. Rondot, and S. Askienazy, A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia, Eur. J. Nucl. Med. 18: 3–11 (1991).
K. Kawabata, H. Tachibana, M. Sugita, and M. Fukuchi, A comparative I-123 SPECT study in Binswanger’s disease and Alzheimer’s disease, Clin. Nucl. Med. 18: 329–336 (1993).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kawabata, K., Tachibana, H., Tomino, Y., Takeda, M., Okuda, B., Sugita, M. (1995). Alzheimer’s Disease and Parkinson’s Disease with Dementia: Comparison of Cortical Blood Flow Demonstrated by Three-Dimensional Surface Display. In: Hanin, I., Yoshida, M., Fisher, A. (eds) Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 44. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9145-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9145-7_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9147-1
Online ISBN: 978-1-4757-9145-7
eBook Packages: Springer Book Archive